EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation.
Cooper RS, Sutherland C, Smith LM, Cowan G, Barnett M, Mitchell D, McLean C, Imlach S, Hayes A, Zahra S, Manchanayake C, Vickers MA, Graham G, McGowan NWA, Turner ML, Campbell JDM, Fraser AR.
Cooper RS, et al. Among authors: turner ml.
Front Immunol. 2024 Jul 1;15:1412211. doi: 10.3389/fimmu.2024.1412211. eCollection 2024.
Front Immunol. 2024.
PMID: 39011042
Free PMC article.